Toggle light / dark theme

In a new publication in Nature Plants, assistant professor of Plant Science at the University of Maryland Yiping Qi has established a new CRISPR genome engineering system as viable in plants for the first time: CRISPR-Cas12b. CRISPR is often thought of as molecular scissors used for precision breeding to cut DNA so that a certain trait can be removed, replaced, or edited. Most people who know CRISPR are likely thinking of CRISPR-Cas9, the system that started it all. But Qi and his lab are constantly exploring new CRISPR tools that are more effective, efficient, and sophisticated for a variety of applications in crops that can help curb diseases, pests, and the effects of a changing climate. With CRISPR-Cas12b, Qi is presenting a system in plants that is versatile, customizable, and ultimately provides effective gene editing, activation, and repression all in one system.

“This is the first demonstration of this new CRISPR-Cas12b system for plant genome engineering, and we are excited to be able to fill in gaps and improve systems like this through new technology,” says Qi. “We wanted to develop a full package of tools for this system to show how useful it can be, so we focused not only on editing, but on developing gene repression and activation methods.”

It is this complete suite of methods that has ultimately been missing in other CRISPR systems in . The two major systems available before this paper in plants were CRISPR-Cas9 and CRISPR-Cas12a. CRISPR-Cas9 is popular for its simplicity and for recognizing very short DNA sequences to make its cuts in the genome, whereas CRISPR-Cas12a recognizes a different DNA targeting sequence and allows for larger staggered cuts in the DNA with additional complexity to customize the system. CRISPR-Cas12b is more similar to CRISPR-Cas12a as the names suggest, but there was never a strong ability to provide gene activation in plants with this system. CRISPR-Cas12b provides greater efficiency for gene activation and the potential for broader targeting sites for , making it useful in cases where genetic expression of a trait needs to be turned on/up (activation) or off/down (repression).

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don’t Threaten. Threats of harming another person will not be tolerated. Be Truthful. Don’t knowingly lie about anyone or anything. Be Nice. No racism, sexism or any sort of –ism that is degrading to another person. Be Proactive. Use the ‘Report’ link on each comment to let us know of abusive posts. Share with Us. We’d love to hear eyewitness accounts, the history behind an article.

Researchers at Princeton University have revealed the inner workings of a gene repression mechanism in fruit fly embryos, adding insight to the study of human diseases.

Led by graduate student Shannon Keenan, the team used light to activate in developing and traced the effects on a protein called Capicua, or Cic. Located in a cell’s nucleus, Cic binds to DNA and performs the specialized task of silencing . The study, published in Developmental Cell and made available online March 5, reveals the dynamics of gene repression by this protein.

In a complex piece of music, the silences running through the melody contribute as much to the score’s effect as the sounded notes. The that control development rely on highly sophisticated temporal patterns of gene activation and repression to create life’s beautiful symphonies. When a pattern is disrupted, it’s like a wrong note in the music. In this case, Cic is a repressor protein that silences certain parts of the genome, allowing other genes to express in harmony with one another. Understanding how repressors like Cic work allows researchers to better conduct the orchestra.

The origins are still too unknown. This is entirely new life a more parasitic lifeform. Bit still new lifeforms entirely. My experiencers tell me of alien origin though the rate of spread also the complexity. No human could make this no even government can make this. We can mimic life not create something new. Sure new things can be added but the signature tells me it is definitely of alien origin. Not even nature can create something this quick nor even governments. Sure there may be like similar things but why does it spread so fast in near systematic precision. Which leads to essentially of exterrestial origin. This is essentially new life we are dealing with.


Nat Rev Microbiol. 2019 Mar;17:181–192. doi: 10.1038/s41579-018‑0118-9.

Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic viruses that emerged in humans at the beginning of the 21st century. Both viruses likely originated in bats, and genetically diverse coronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide. In this Review, we summarize the current knowledge on the origin and evolution of these two pathogenic coronaviruses and discuss their receptor usage; we also highlight the diversity and potential of spillover of bat-borne coronaviruses, as evidenced by the recent spillover of swine acute diarrhoea syndrome coronavirus (SADS-CoV) to pigs.

In the past few decades, researchers discovered that the rate at which we age is strongly influenced by biochemical processes that, at least in animal models, can be controlled in the laboratory. Telomere shortening is one of these processes; another is the ability of cells to detect nutrients mediated by the mTOR protein. Researchers have been able to prolong life in many species by modifying either one of them. But what if they manipulate both?

A team from the Spanish National Cancer Research Centre (CNIO) has studied it for the first time, with unexpected results. Blocking nutrient sensing by treatment with rapamycin, an mTOR inhibitor, delays the aging of healthy , but curiously, it worsens diseases and premature aging that occur in mice with short telomeres. This finding has important implications for the treatment of diseases associated with short telomeres, but also for that are also associated with short telomeres. The study, done by the Telomeres and Telomerase Group headed by Maria Blasco at the CNIO, is published in Nature Communications with Iole Ferrara-Romeo as the first author.

Telomeres, regions of repetitive nucleotide sequences at the end of chromosomes, preserve the genetic information of the cells. They shorten with age until they can no longer fulfill their function: The cells stop dividing and the tissues age since they are no longer able to regenerate.

Would you want to know if you’re at risk of Alzheimer’s disease, for example?


The integration of sequencing into health care doesn’t fit very well in the model of how medicine is practiced today, but is well aligned with the future vision of health care that so many of us have — a vision that focuses upon prediction and prevention.

We imagine that personal genome sequencing could play a central role in bringing about a more personalized and participatory form of medicine — including a health care system where patients have more knowledge of their own risks and diagnoses and are empowered to act upon that information.

Gene therapy is the introduction of DNA into a patient to treat a genetic disease or a disorder. The newly inserted DNA contains a correcting gene to correct the effects of a disease, causing mutations. Gene therapy is a promising treatment for genetic diseases and also includes cystic fibrosis and muscular dystrophy. Gene therapy is a suitable treatment for infectious diseases, inherited disease and cancer.

Over the last few centuries, infectious diseases have been understood and tackled, through advances in sanitation, anti-microbial medications and vaccination. One day we may also be able to tackle genetic diseases – lifelong conditions arising from mutations that we inherit from our ancestors or that occur during our development.

My editorial from today’s (3/18/19) Financial Times:

Far sooner than most people realise, the genetics revolution will transform the world within and around us. Although we think about genetic technologies primarily in the context of healthcare, these tools are set to change the way we make babies, the nature of the babies we make and, ultimately, our evolutionary trajectory as a species — and we are not remotely ready for what’s coming. Yet we must be, to optimise the benefits and minimise the potential harms of genetic technologies.

Scientists are now able to manipulate biology to a previously unimaginable degree. In the past year, we’ve seen two female mice having their own babies, dramatic increases in the precision of gene-editing tools, and the birth in China of the first gene-edited humans. As this science advances exponentially, however, the regulations guiding how it should best be used are struggling to keep up. If the applications race forward without appropriate guard rails, the danger increases that more scientists like He Jiankui, the Chinese biophysicist who genetically altered two girls, will put people’s health at risk. But if the regulations are hastily written before the issues are clear, are too strong or are not flexible enough, many people who would otherwise have benefited from applied genetic technologies will be condemned to unnecessary suffering or even death.

For the first time, doctors have attempted to cure blindness by gene-hacking a patient with CRISPR technology.

A team from Oregon Health & Science Institute injected three droplets of fluid that delivered the CRISPR DNA fragments directly into a patient’s eyeball, The Associated Press reports, in hopes that it will reverse a rare genetic condition called Leber congenital amaurosis, which causes blindness early in childhood.

“We literally have the potential to take people who are essentially blind and make them see,” Charles Albright, chief scientific officer of Editas Medicine, told the AP.

Scientists say they have used the gene editing tool CRISPR inside someone’s body for the first time — offering a new frontier for efforts to operate on DNA, the chemical code of life, to treat diseases.

A patient recently had it done at the Casey Eye Institute at Oregon Health & Science University in Portland for an inherited form of blindness, according to the companies that make the treatment. The company would not give details on the patient or when the surgery occurred.

It may take up to a month to see if it worked to restore the patient’s vision. If the first few attempts seem safe, doctors plan to test it on 18 children and adults.